[HTML][HTML] Engineering the next generation of cell-based therapeutics
Cell-based therapeutics are an emerging modality with the potential to treat many currently
intractable diseases through uniquely powerful modes of action. Despite notable recent …
intractable diseases through uniquely powerful modes of action. Despite notable recent …
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies
Cardiac fibrosis remains an unresolved problem in heart diseases. After initial injury, cardiac
fibroblasts (CFs) are activated and subsequently differentiate into myofibroblasts (myoFbs) …
fibroblasts (CFs) are activated and subsequently differentiate into myofibroblasts (myoFbs) …
[HTML][HTML] Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair
Cardiac patches are an effective way to deliver therapeutics to the heart. However, such
procedures are normally invasive and difficult to perform. Here, we develop and test a …
procedures are normally invasive and difficult to perform. Here, we develop and test a …
[HTML][HTML] Biomaterials to enhance stem cell transplantation
The successful transplantation of stem cells has the potential to transform regenerative
medicine approaches and open promising avenues to repair, replace, and regenerate …
medicine approaches and open promising avenues to repair, replace, and regenerate …
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN …
Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II
trial designed to determine whether treatment with autologous bone marrow‐derived …
trial designed to determine whether treatment with autologous bone marrow‐derived …
Heart regeneration by endogenous stem cells and cardiomyocyte proliferation: controversy, fallacy, and progress
Ischemic heart disease is the leading cause of death worldwide. Myocardial infarction
results in an irreversible loss of cardiomyocytes with subsequent adverse remodeling and …
results in an irreversible loss of cardiomyocytes with subsequent adverse remodeling and …
Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine
L Gao, L Wang, Y Wei, P Krishnamurthy… - Science translational …, 2020 - science.org
Cell therapy treatment of myocardial infarction (MI) is mediated, in part, by exosomes
secreted from transplanted cells. Thus, we compared the efficacy of treatment with a mixture …
secreted from transplanted cells. Thus, we compared the efficacy of treatment with a mixture …
[HTML][HTML] Harnessing the potential of hydrogels for advanced therapeutic applications: Current achievements and future directions
P Lu, D Ruan, M Huang, M Tian, K Zhu… - … and Targeted Therapy, 2024 - nature.com
The applications of hydrogels have expanded significantly due to their versatile, highly
tunable properties and breakthroughs in biomaterial technologies. In this review, we cover …
tunable properties and breakthroughs in biomaterial technologies. In this review, we cover …
Endothelial extracellular vesicles contain protective proteins and rescue ischemia-reperfusion injury in a human heart-on-chip
Extracellular vesicles (EVs) derived from various stem cell sources induce cardioprotective
effects during ischemia-reperfusion injury (IRI). These have been attributed mainly to the …
effects during ischemia-reperfusion injury (IRI). These have been attributed mainly to the …
Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review
This paper aims to provide an important update on the recent preclinical and clinical trials
using cell therapy strategies and engineered heart tissues for the treatment of postinfarction …
using cell therapy strategies and engineered heart tissues for the treatment of postinfarction …